ClinicalTrials.Veeva

Menu

Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis

Amgen logo

Amgen

Status and phase

Completed
Phase 3

Conditions

Pediatric Plaque Psoriasis

Treatments

Drug: Etanercept

Study type

Interventional

Funder types

Industry

Identifiers

NCT00141921
20050111

Details and patient eligibility

About

The purpose of this study is to evaluate the long-term safety and efficacy of etanercept in pediatric patients with moderate to severe psoriasis.

Full description

This study was a multicenter, open-label extension study for pediatric patients who participated in Study 20030211 (NCT00078819).

Enrollment

182 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Enrollment on previous Amgen study 20030211 (NCT00078819)

Exclusion criteria

  • Serious or clinically significant adverse event on Amgen study 20030211 related to etanercept

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

182 participants in 1 patient group

Etanercept
Experimental group
Description:
Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
Treatment:
Drug: Etanercept

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems